All In Biotech

Drug Trial Radar · NCT07193511

BEACON-1: Study of AVZO-103 as a Single Agent and in Combination Therapy in Patients With Locally Advanced or Metastatic Urothelial Cancer or Other Solid Tumors (AVZO-103-1001)

A Phase 1/2, First-in-Human Study to Assess the Safety, Tolerability, Pharmacokinetics, Pharmacodynamics, and Antitumor Activity of AVZO-103, a Nectin4/Trop2 ADC, as a Single Agent and in Combination Therapy in Patients With Locally Advanced or Metastatic Urothelial Cancer or Other Solid Tumors

Last checked: Nov 19, 2026Latest source record: Oct 5, 2026 (this record)Source: ClinicalTrials.govMethods & limitations

Recruiting

Status

Recruiting

Enrollment

355

Planned (sponsor's estimate)

Start

Oct 2, 2025

Primary completion

Mar 2030

Study completion Sep 2030

Sponsor

Lead sponsor
Avenzo Therapeutics, Inc.Industry
Sponsor type
Industry
First posted
Sep 26, 2025

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 1 / Phase 2
Allocation
Non randomized
Model
Sequential
Masking
None
Primary purpose
Treatment
FDA-regulated drug
Yes
Who can join
All sexes, from 18 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

This study, the first clinical trial of AVZO-103, aims to determine the safety, tolerability, pharmacokinetics, pharmacodynamics, maximum tolerated dose, and antitumor activity of AVZO-103 when administered intravenously as a monotherapy and in combination therapy to patients with locally advanced or metastatic urothelial cancer or other solid tumors.

Conditions

  • Solid Tumor Cancer
  • Locally Advanced
  • Metastatic Solid Tumors
  • Urothelial Cancer

Interventions

  • AVZO-103Drug

    Specific dose in protocol specified schedule

  • Combination AgentDrug

    Per label based on combination agent used

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Occurrence of Dose Limiting Toxicities (DLTs) during the first cycle (Phase 1)Time frame: Approximately 2 years
  2. Determine the maximum tolerated dose (MTD) and/or preliminary recommended Phase 2 dose (RP2D) (Phase 1)Time frame: Approximately 16 months
  3. Number of Participants with Treatment Emergent Adverse Events (TEAEs) and lab abnormalities (Phase 1)Time frame: From baseline until end of study treatment or study completion (approximately 2 years)
  4. Objective Response Rate (ORR) (Phase 2)Time frame: From baseline through disease progression or study completion (approximately 2 years)

Locations

15 sites in 1 country. Site status is shown where the registry gives one.

  • Avenzo Therapeutics Recruiting Site

    San Francisco, California · Recruiting

  • Avenzo Therapeutics Recruiting Site

    Aurora, Colorado · Recruiting

  • Avenzo Therapeutics Recruiting Site

    New Haven, Connecticut · Recruiting

  • Avenzo Therapeutics Recruiting Site

    Orlando, Florida · Recruiting

  • Avenzo Therapeutics Recruiting Site

    Tampa, Florida · Recruiting

  • Avenzo Therapeutics Recruiting Site

    Boston, Massachusetts · Recruiting

  • Avenzo Therapeutics Recruiting Site

    New York, New York · Recruiting

  • Avenzo Therapeutics Recruiting Site

    Chapel Hill, North Carolina · Recruiting

  • Avenzo Therapeutics Recruiting Site

    Cleveland, Ohio · Recruiting

  • Avenzo Therapeutics Recruiting Site

    Oklahoma City, Oklahoma · Recruiting

  • Avenzo Therapeutics Recruiting Site

    Myrtle Beach, South Carolina · Recruiting

  • Avenzo Therapeutics Recruiting Site

    Nashville, Tennessee · Recruiting

  • Avenzo Therapeutics Recruiting Site

    Austin, Texas · Recruiting

  • Avenzo Therapeutics Recruiting Site

    Houston, Texas · Recruiting

  • Avenzo Therapeutics Recruiting Site

    Irving, Texas · Recruiting

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.